METAVIA INC Overview

METAVIA INC (Nasdaq: MTVA) is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, focused on developing therapies for cardiometabolic diseases. Its primary programs include the GPR119 agonist vanoglipel (DA-1241) and the dual GLP-1/glucagon receptor agonist DA-1726.

Company Overview

Founded in 2017, METAVIA INC aims to address cardiometabolic disorders. The company's pipeline includes DA-1241, an oral G-protein-coupled receptor 119 (GPR119) agonist designed to reduce liver inflammation and fibrosis in metabolic dysfunction-associated steatohepatitis (MASH), and DA-1726, a once-weekly subcutaneous oxyntomodulin analogue targeting obesity through dual glucagon-like peptide-1 and glucagon receptor activation.

Corporate Structure

METAVIA employs between 11 and 50 professionals and collaborates with its strategic partner and major investor, Dong-A ST Co. Ltd. This partnership provides access to research, development, and chemistry, manufacturing, and controls (CMC) capabilities. The company's leadership, based in Cambridge, Massachusetts, manages global collaborations, including an August 2025 agreement with AI-driven drug discovery firm Syntekabio, Inc.

Biotechnology by Louis Reed

Developments and News

On November 6, 2025, METAVIA reported its third-quarter financial results, indicating it held $14.3 million in cash as of September 30, 2025, which is expected to fund operations into 2026. During this quarter, the Phase 1 trial of DA-1726 presented data at ObesityWeek® 2025 (November 4–7), reporting a mean body-weight reduction of up to 6.3 percent in the 32 mg cohort and supporting once-weekly dosing based on pharmacokinetic data. The study was extended to include an eight-week, 48 mg cohort, with topline results anticipated by December 31, 2025.

On November 7, 2025, two abstracts concerning DA-1726 were accepted for presentation at the AASLD Liver Meeting (November 7–11). Full data from a 16-week Phase 2a study of vanoglipel will also be presented at this meeting. Additionally, management plans to hold an end-of-Phase 2 discussion with the U.S. Food and Drug Administration in the first half of 2026.

On December 2, 2025, METAVIA announced a 1-for-11 reverse stock split effective December 4, with trading on a split-adjusted basis beginning December 5 under its existing ticker “MTVA.” This reverse split reduced outstanding shares from approximately 25.4 million to 2.3 million, maintaining a par value of $0.001 and 100 million authorized shares.

Financial and Strategic Analysis

As of December 10, 2025, MTVA shares closed at $10.91, reflecting an increase of 26.27 percent with a trading volume of 125,277 on NASDAQ. Key metrics include a market capitalization of $24.0 million and 2.20 million shares outstanding. The trailing-twelve-month EPS stands at –$13.88, with a TTM P/E ratio of –0.79. The company does not currently generate revenue and reported R&D expenses of $1.9 million in Q3 2025 compared to $4.5 million in Q3 2024. Its cash runway into 2026 supports ongoing trials for DA-1726 and vanoglipel.

Market Position and Industry Context

Operating within the GLP-1 therapeutics market, METAVIA is positioned among early-stage biotechs targeting obesity and MASH. Analysts project this market to grow at a compounded annual growth rate of approximately 17.5 percent through 2030. Competitors include established entities such as Eli Lilly and Novo Nordisk. METAVIA’s dual-agonist and oral GPR119 programs differentiate its pipeline, though the company faces common clinical-stage risks, including trial outcomes, regulatory approvals, and capital requirements.

tl;dr

On November 6, 2025, METAVIA reported Q3 results with $14.3 million in cash and extended its DA-1726 Phase 1 trial to eight weeks, expecting topline data by December 31, 2025. Two DA-1726 abstracts were accepted for presentation at the AASLD meeting (November 7–11), and an FDA meeting regarding vanoglipel (DA-1241) is planned for H1 2026. A 1-for-11 reverse stock split took effect December 4, 2025, with shares trading at $10.91 (+26.27 percent) on December 10.